NYSE:COO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

The Cooper Companies, Inc. operates as a medical device company worldwide. More Details


Snowflake Analysis

Moderate growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Cooper Companies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: COO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.2%

COO

-1.2%

US Medical Equipment

-2.4%

US Market


1 Year Return

23.9%

COO

24.3%

US Medical Equipment

18.2%

US Market

Return vs Industry: COO matched the US Medical Equipment industry which returned 24.4% over the past year.

Return vs Market: COO exceeded the US Market which returned 19.5% over the past year.


Shareholder returns

COOIndustryMarket
7 Day-2.2%-1.2%-2.4%
30 Day0.6%4.5%4.2%
90 Day20.2%7.0%6.3%
1 Year23.9%23.9%25.3%24.3%20.9%18.2%
3 Year45.5%45.4%74.7%70.2%41.2%31.8%
5 Year138.1%137.8%152.1%132.4%84.8%63.9%

Price Volatility Vs. Market

How volatile is Cooper Companies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cooper Companies undervalued compared to its fair value and its price relative to the market?

61.59x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: COO ($348.42) is trading above our estimate of fair value ($255.51)

Significantly Below Fair Value: COO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: COO is poor value based on its PE Ratio (61.6x) compared to the US Medical Equipment industry average (51.1x).

PE vs Market: COO is poor value based on its PE Ratio (61.6x) compared to the US market (19x).


Price to Earnings Growth Ratio

PEG Ratio: COO is poor value based on its PEG Ratio (2.7x)


Price to Book Ratio

PB vs Industry: COO is overvalued based on its PB Ratio (4.5x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Cooper Companies forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

22.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COO's forecast earnings growth (22.5% per year) is above the savings rate (2.2%).

Earnings vs Market: COO's earnings (22.5% per year) are forecast to grow faster than the US market (22.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: COO's revenue (8.1% per year) is forecast to grow slower than the US market (10% per year).

High Growth Revenue: COO's revenue (8.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COO's Return on Equity is forecast to be low in 3 years time (12.9%).


Next Steps

Past Performance

How has Cooper Companies performed over the past 5 years?

12.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COO has high quality earnings.

Growing Profit Margin: COO's current net profit margins (11.4%) are lower than last year (17.1%).


Past Earnings Growth Analysis

Earnings Trend: COO's earnings have grown by 12.6% per year over the past 5 years.

Accelerating Growth: COO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: COO had negative earnings growth (-37.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (2.5%).


Return on Equity

High ROE: COO's Return on Equity (7.4%) is considered low.


Next Steps

Financial Health

How is Cooper Companies's financial position?


Financial Position Analysis

Short Term Liabilities: COO's short term assets ($1.3B) exceed its short term liabilities ($1.1B).

Long Term Liabilities: COO's short term assets ($1.3B) do not cover its long term liabilities ($1.9B).


Debt to Equity History and Analysis

Debt Level: COO's debt to equity ratio (50.6%) is considered high.

Reducing Debt: COO's debt to equity ratio has increased from 48.6% to 50.6% over the past 5 years.

Debt Coverage: COO's debt is well covered by operating cash flow (24.6%).

Interest Coverage: COO's interest payments on its debt are well covered by EBIT (9.3x coverage).


Balance Sheet


Next Steps

Dividend

What is Cooper Companies's current dividend yield, its reliability and sustainability?

0.017%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: COO's dividend (0.017%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.62%).

High Dividend: COO's dividend (0.017%) is low compared to the top 25% of dividend payers in the US market (4.66%).


Stability and Growth of Payments

Stable Dividend: COO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: COO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: COO is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of COO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Al White (50 yo)

2.42yrs

Tenure

US$7,724,745

Compensation

Mr. Albert G. White, III, also known as Al, has been President, Director and Chief Executive Officer of The Cooper Companies since May 1, 2018. Mr. White served as Chief Financial Officer of The Cooper Com ...


CEO Compensation Analysis

Compensation vs Market: Al's total compensation ($USD7.72M) is below average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Al's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Albert White
President2.42yrsUS$7.72m0.084%
$ 14.4m
Brian Andrews
Senior VP2.42yrsUS$1.99m0.0060%
$ 1.0m
Daniel McBride
Executive VP & COO6.92yrsUS$3.58m0.070%
$ 11.9m
Robert Auerbach
Special Advisor to the CEO0.25yrUS$1.86m0.0029%
$ 488.7k
Holly Sheffield
President of CooperSurgical Inc0.25yrUS$2.51m0.0055%
$ 939.8k
Agostino Ricupati
Senior VP of Finance & Tax and Chief Accounting Officer3yrsUS$1.21m0.0040%
$ 683.5k
Kim Duncan
Vice President of Investor Relations & Risk Management5.92yrsno datano data
Mark Drury
VP, General Counsel & Corporate Secretary0.67yrno data0.0015%
$ 264.8k
Randal Golden
Legal Advisor5.92yrsno data0.0034%
$ 582.7k
Juan Aragón
President of CooperVision Specialty EyeCare Division2.67yrsno datano data

2.5yrs

Average Tenure

53yo

Average Age

Experienced Management: COO's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Albert White
President2.42yrsUS$7.72m0.084%
$ 14.4m
Allan Rubenstein
Independent Vice Chairman & Lead Director18.25yrsUS$472.28k0.0065%
$ 1.1m
A. Bender
Independent Chairman18.25yrsUS$594.40k0.038%
$ 6.5m
Robert Weiss
Non-Independent Director24.75yrsUS$375.48k0.29%
$ 49.5m
William Kozy
Independent Director4.5yrsUS$447.46k0.0080%
$ 1.4m
Gary Petersmeyer
Independent Director7.75yrsUS$452.46k0.0027%
$ 466.5k
Jody Lindell
Independent Director14.75yrsUS$467.96k0.038%
$ 6.6m
Colleen Jay
Independent Director4.5yrsUS$448.46k0.0075%
$ 1.3m

11.3yrs

Average Tenure

71yo

Average Age

Experienced Board: COO's board of directors are seasoned and experienced ( 11.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: COO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

The Cooper Companies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: The Cooper Companies, Inc.
  • Ticker: COO
  • Exchange: NYSE
  • Founded: 1980
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$17.087b
  • Shares outstanding: 49.04m
  • Website: https://www.coopercos.com

Number of Employees


Location

  • The Cooper Companies, Inc.
  • 6101 Bollinger Canyon Road
  • Suite 500
  • San Ramon
  • California
  • 94583
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
COONYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1983
CP6DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1983
COO *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1983
0I3ILSE (London Stock Exchange)YesCommon StockGBUSDJan 1983
C1OO34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 10 REPR 1 COMBRBRLJan 2020

Biography

The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of con ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 00:26
End of Day Share Price2020/10/19 00:00
Earnings2020/07/31
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.